Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Containing bla(VIM-2) and Elements of Salmonella Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio

Federico Perez, Case Western Reserve University
Andrea M. Hujer, Case Western Reserve University
Steven H. Marshall, Louis Stokes Cleveland Department of Veterans Affairs Medical Center
Amy J. Ray, Case Western Reserve University
Philip Rather, Emory University
Nuntra Suwantarat, University Hospitals Case Medical Center
Donald Dumford, University Hospitals Case Medical Center
Patrick O'Shea, Louis Stokes Cleveland Department of Veterans Affairs Medical Center
T. Nicholas J. Domitrovic, Louis Stokes Cleveland Department of Veterans Affairs Medical Center
Robert A. Salata, Case Western Reserve University

Only first 10 authors above; see publication for full author list.

Journal Title: Antimicrobial Agents and Chemotherapy
Volume: Volume 58, Number 10
Publisher: American Society for Microbiology | 2014-10-01, Pages 5929-5935
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1128/AAC.02372-14
Permanent URL: https://pid.emory.edu/ark:/25593/s1rr5

Final published version: http://dx.doi.org/10.1128/AAC.02372-14

Copyright information:
© 2014, American Society for Microbiology. All Rights Reserved.

Accessed January 4, 2020 5:13 AM EST
Extensively Drug-Resistant *Pseudomonas aeruginosa* Isolates Containing *bla*\textsubscript{VIM-2} and Elements of *Salmonella* Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio

Federico Perez,\textsuperscript{a,b} Andrea M. Hujer,\textsuperscript{a,b} Steven H. Marshall,\textsuperscript{a} Amy J. Ray,\textsuperscript{b,f} Philip N. Rather,\textsuperscript{b,h} Nuntra Suwantarat,\textsuperscript{f} Donald Dumford III,\textsuperscript{j} Patrick O’Shea,\textsuperscript{a} T. Nicholas J. Domitrovic,\textsuperscript{a} Robert A. Salata,\textsuperscript{b,f} Kalyan D. Chavda,\textsuperscript{j} Liang Chen,\textsuperscript{j} Barry N. Kreiswirth,\textsuperscript{j} Alejandro J. Vila,\textsuperscript{i} Susanne Haussler,\textsuperscript{k} Michael R. Jacobs,\textsuperscript{b,c,f} Robert A. Bonomo,\textsuperscript{a,b,d,e}

Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA; Department of Medicine;\textsuperscript{d} Department of Pathology;\textsuperscript{e} Department of Molecular Biology and Microbiology,\textsuperscript{a} and Department of Pharmacology,\textsuperscript{a} Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; University Hospitals Case Medical Center, Cleveland, Ohio, USA;\textsuperscript{d} Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA;\textsuperscript{f} Research Service, Department of Veterans Affairs Medical Center, Decatur, Georgia, USA;\textsuperscript{g} Public Health Research Institute Center, New Jersey Medical School-Rutgers University, Newark, New Jersey, USA; Instituto de Biología Molecular y Celular de Rosario, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina; Hannover Medical School and Helmholtz Center for Infection Research, Hannover, Germany\textsuperscript{h}

Carbapenems are a mainstay of treatment for infections caused by *Pseudomonas aeruginosa*. Carbapenem resistance mediated by metallo-β-lactamases (MBLs) remains uncommon in the United States, despite the worldwide emergence of this group of enzymes. Between March 2012 and May 2013, we detected MBL-producing *P. aeruginosa* in a university-affiliated health care system in northeast Ohio. We examined the clinical characteristics and outcomes of patients, defined the resistance determinants and structure of the genetic element harboring the *bla*\textsubscript{VIM-2} gene through genome sequencing, and typed MBL-producing *P. aeruginosa* isolates using pulsed-field gel electrophoresis (PFGE), repetitive sequence-based PCR (rep-PCR), and multilocus sequence typing (MLST). Seven patients were affected that were hospitalized at three community hospitals, a long-term-care facility, and a tertiary care center; one of the patients died as a result of infection. Isolates belonged to sequence type 233 (ST233) and were extensively drug resistant (XDR), including resistance to all fluoroquinolones, aminoglycosides, and β-lactams; two isolates were nonsusceptible to colistin. The *bla*\textsubscript{VIM-2} gene was identified as *bla*\textsubscript{VIM-2} contained within a class 1 integron (In559), similar to the cassette array previously detected in isolates from Norway, Russia, Taiwan, and Chicago, IL. Genomic sequencing and assembly revealed that In559 was part of a novel 35-kb region that also included a Tn501-like transposon and *Salmonella* genomic island 2 (SGI2)-homologous sequences. This analysis of XDR strains producing VIM-2 from northeast Ohio revealed a novel recombination event between *Salmonella* and *P. aeruginosa*, heralding a new antibiotic resistance threat in this region’s health care system.

Successful treatment of infections caused by *Pseudomonas aeruginosa* depends on the early administration of effective antimicrobial therapy (1). Carbapenems have been among the most active antibiotics against *P. aeruginosa*; unfortunately, carbapenem-resistant *P. aeruginosa* is increasingly prevalent (2–4). Carbapenem resistance in *P. aeruginosa* is most often caused by mechanisms associated with antibiotic-mediated selection of mutants, such as loss of the OprD porin and overexpression of cephalosporinas and efflux pumps. Additionally, *P. aeruginosa* can acquire resistance through horizontal transfer of mobile genetic elements encoding enzymes that inactivate carbapenems, including metallo-β-lactamases (MBLs) (5).

Resistance mediated by MBLs, able to hydrolyze all β-lactams except monobactams, is an emerging problem among *P. aeruginosa* isolates in many countries of Asia, Europe, Africa, and South America (6–10). One of the MBLs of foremost global importance is the *Verona* integron-encoded metallo-β-lactamase (VIM). Currently, MBL-mediated carbapenem resistance is infrequent in the United States although national surveillance programs have detected *bla*\textsubscript{VIM-2} in *P. aeruginosa* and other bacteria (11–17). At the local and regional levels, the early detection of MBL-producing bacteria by clinical microbiology laboratories and the molecular characterization of these bacteria can help inform efforts to prevent and control their dissemination.

Here, we report the dissemination of *P. aeruginosa* isolates containing VIM-2 in patients from community hospitals in northeast Ohio. These isolates displayed an extensively drug resistant (XDR) phenotype, leaving few, if any, treatment options (18). As this was a “sentinel event” in our region, our objective was to define the molecular characteristics of the outbreak strain and to place it in the global context of MBL-producing *P. aeruginosa*. These analyses led us to discover a genetic element that represents a novel recombination event between elements found in *P. aeruginosa* and *Salmonella*.
MATERIALS AND METHODS

Selection of bacterial isolates. University Hospitals is an integrated health care system consisting of a tertiary care medical center, six community hospitals, and a long-term-care facility located in northeast Ohio, served by a central clinical microbiology laboratory that processes approximately 250,000 cultures a year. A laboratory-based surveillance program was established in 2007 to detect and characterize carbapenem resistance among Gram-negative bacteria across the hospital system (19). Clinical isolates of P. aeruginosa for which the imipenem or meropenem MIC was $\geq 4 \mu g/ml$ were screened for the presence of acquired carbapenemases using a modified Hodge test (mHT) with imipenem and for the presence of MBLs using imipenem-EDTA Etest strips (bioMérieux, Athens, GA). A 3-fold reduction in the imipenem MIC in the presence of EDTA triggered genetic testing for bla<sub>MBL</sub> (20, 21). Antimicrobial susceptibility testing (AST) was performed using the MicroScan System (Siemens, Tarrytown, NY), and results were interpreted according to Clinical and Laboratory Standards Institute guidelines (22).

Molecular typing PFGE and rep-PCR. Molecular typing of P. aeruginosa isolates containing VIM-2 was performed with pulsed-field gel electrophoresis (PFGE) using the restriction enzyme SpeI for digestion and previously described analysis criteria (23, 24). Genetic similarity of VIM-2-harboring P. aeruginosa isolates was also investigated by repetitive-sequence-based-PCR (rep-PCR). Bacterial DNA was extracted using an MoBio UltraClean microbial isolation kit (MoBio, Carlsbad, CA) and amplified using a DiversiLab Pseudomonas kit. Amplicons were separated by electrophoresis on microfluidic chips and analyzed on an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). Resulting band patterns were compared via the Pearson correlation method, using DiversiLab software (bioMérieux). Isolates with $\geq 95\%$ similarity were considered genetically related (17).

MLST. Multilocus sequence typing (MLST) was performed on P. aeruginosa isolates harboring VIM-2 according to the method of Curran et al. (25). Seven housekeeping genes (acoA, aroE,guaA,mutL, nuoB,ppgA, and trpE) were amplified by PCR and sequenced. Sequences were compared to existing alleles, and allelic numbers and sequence types (STs) were assigned according to the Pseudomonas aeruginosa public MLST database (http://pubmlst.org/paeruginosa/).

PCR amplification and sequencing of genes encoding β-lactamases and aminoglycoside resistance enzymes. Among isolates with a positive mHT, PCR amplification of bla<sub>TEM</sub>, bla<sub>KPC</sub>, bla<sub>NDM</sub>, and bla<sub>VIM</sub> genes was performed (26). We also tested for the presence of genes encoding aminoglycoside-modifying enzymes (AME) and 16S rRNA methyltransferases using validated primers and PCR conditions as described previously (27, 28). Amplicons were sequenced at Molecular Cloning Laboratories (MCLAB; San Francisco, CA).

Immunoblotting. In order to assess VIM-2 expression, rabbit polyclonal antibodies were raised against purified VIM-2-β-lactamase by New England Peptide and isolated from serum using protein G column purification (Sigma Genosys, The Woodlands, TX). Sample preparation, immunoblotting, and development were performed as previously reported (29, 30).

Mating experiments. To investigate the possibility of conjugative transfer of the bla<sub>VIM</sub>-1 gene, bla<sub>VIM</sub>-2-containing P. aeruginosa isolates susceptible to rifampin were selected for by overnight growth in LB medium along with rifampin-resistant Escherichia coli J-53 or P. aeruginosa PA01 (American Type Culture Collection, Manassas, VA). After overnight culture, cells were plated on Mueller-Hinton agar plates containing 100 mg/liter ampicillin and 100 mg/liter rifampin. Colonies that subsequently grew were replated on the same selective medium and screened by PCR for the presence of bla<sub>VIM</sub>-2.

Genome sequencing and assembly. Further genomic analysis of the P. aeruginosa wound isolate from case 1 was undertaken. Genomic DNA was extracted using a Wizard genomic DNA purification kit (Promega, Madison, WI). Genomic DNA was fragments, and genomic libraries were prepared using an Ion Xpress Plus Fragment Library Kit (Life Technologies, Carlsbad, CA). Whole-genome sequencing was performed using the Ion Torrent Personal Genome Machine (PGM) platform per the manufacturer’s instructions (Life Technologies, Carlsbad, CA). Sequencing reads were assembled into a consensus de novo assembly using CLC genomic workbench software (version 5.5.1; CLC Bio, Aarhus, Denmark). Based on overlapping terminal regions, the contigs were assembled into supercontigs. The bla<sub>VIM</sub>-harboring supercontig was extracted, and the open reading frames (ORFs) were predicted and annotated using the RAST (rast.nmpdr.org) server (31). The IS Finder database (www.is.biotoul.fr) was used to identify the names/numbers of insertion elements that were found using the RAST server. The structure of the bla<sub>VIM</sub>-harboring genomic island was confirmed by long-range PCRs using internal and overlapping primers.

Nucleotide sequence accession number. The nucleotide sequence of the bla<sub>VIM</sub>-harboring genomic island was deposited in GenBank under accession number KJ463833.

RESULTS

Clinical characteristics and antimicrobial susceptibility testing (AST). In the 2-year period of 2012 and 2013, the laboratory received 3,922 single-patient isolates of P. aeruginosa. Among these strains, the prevalence of carbapenem resistance was 20%. As part of our laboratory-based surveillance program, phenotypic testing with the mHT and imipenem/EDTA identified seven patients with MBL-producing P. aeruginosa, representing 0.9% of carbapenem-resistant P. aeruginosa isolates.

The initial isolate of MBL-producing P. aeruginosa (case 1) was detected in March 2012 from a wound in the foot of a 69-year-old man with type 2 diabetes mellitus who resided at a long-term-care facility; the patient also had asymptomatic bacteriuria with XDR P. aeruginosa. The mHT indicated carbapenemase production, and the imipenem MIC was lowered from $>256 \mu g/ml$ to 6 $\mu g/ml$ in the presence of EDTA. MBL-producing P. aeruginosa isolates were similarly detected in isolates from six additional patients (cases 2 to 7) between April 2012 and May 2013 (see Table S1 in the supplemental material). Case 4 had a bloodstream infection and died despite appropriate therapy with aztreonam and colistin. Case 5 was transferred to the tertiary care center from Qatar, in the Persian Gulf. Of note, case 1 was admitted to the same ward in a long-term-care facility where case 3 had resided until 4 days before. Cases 2, 4, 6, and 7 were all treated at the same community hospital, but only cases 6 and 7 had overlapping admissions. Cases 2, 6, and 7 had been residents or were discharged to a second long-term-care facility, which is associated with community hospital 2.

AST (Table 1) indicated that the nine isolates from these seven patients exhibited imipenem MICs of $>8 \mu g/ml$ and were resistant to all other β-lactams, as well as fluoroquinolones and aminoglycosides. Isolates from cases 1, 2 (second isolate), and 3 were additionally resistant to aztreonam and colistin. Isolates from cases 1 and 3 demonstrated intermediate resistance to colistin (MIC of 4 $\mu g/ ml$) whereas all isolates were susceptible to polymyxin B.

Molecular typing, genetic analysis, and immunoblotting. Typing with rep-PCR revealed that all isolates shared $>95\%$ similarity (Fig. 1). PFGE performed on six of the nine isolates demonstrated that all isolates were closely related ($<3$ band differences) (data not shown). MLST classified all isolates as P. aeruginosa sequence type 233 (ST233). PCR detected bla<sub>VIM</sub>-2 in all MBL-producing P. aeruginosa isolates, while other carbapenemase genes were absent.

Attempts to transfer the bla<sub>VIM</sub>-2 gene to P. aeruginosa PA01 or E. coli J-53 were unsuccessful. A 3.2-kb Tn402-like class 1 integron fragment was amplified in all isolates with the following primers:
intI1 forward, 5'-GCAAGCGCCGCGAGCCGAC-3'; mtc reverse, 5'-GAAACCAAGGTGGGCAG-3'. Analysis of this molecular genetic element revealed two aminoglycoside-modifying enzyme (AME) genes: aacA7, a gene conferring resistance to amikacin and tobramycin, and aacC-A5, conveying resistance to gentamicin. Other AME or 16S rRNA methyltransferase genes were not detected. Steady-state protein expression assessed by Western blot analysis revealed that the VIM-2 β-lactamase was expressed at similar levels in all isolates tested (data not shown).

Structure of a blaVIM-2-harboring genomic island. Further analysis of the genetic environment of the VIM-2-producing P. aeruginosa wound isolate from case 1 revealed a genomic island harboring blaVIM-2 that is 34,954 bp in length and harbors 37 predicted ORFs (Fig. 2). This genomic island is integrated into the chromosome within a gene encoding the phosphate ABC transporter substrate-binding protein (PA5101 in P. aeruginosa PAO1). The whole region is bounded by 38-bp Tn3-like transposon-associated invert repeats (IRs), flanked by 6-bp duplications (TTTTCA) of the target sequence (target site duplications [TSD]). This recombinant element carries resistance to β-lactams (blaVIM-2 and blaOXA-4), aminoglycosides (aadA2, aacA7, and aacC-A5), tetracycline (tetA), chloramphenicol (cmlA6 and cmlA9), trimethoprim (dfrB5), antiseptics (qacE), sulfonamides (sul1), and mercury (a mer operon) (Fig. 2).

The upstream 19-kb region is a Tn501-like transposon (93% identical to Tn501) that includes genes encoding a transposase (tnpA) and a resolvase (tnpR), an inserted blaVIM-2-harboring class 1 integron, and a mer operon (Fig. 2). The tnpA (2,967 bp) and tnpR (561 bp) genes are 97.4% and 99.8% identical, respectively, to those of Tn501 from P. aeruginosa plasmid pVS1 (GenBank accession number Z00027). The Tn402-like class 1 integron, carrying an aacA7-blaVIM-2-dfrB5-aacC-A5 gene cassette array, is inserted downstream of the tnpR gene, generating a 5-bp duplication sequence (GCCCT) adjacent to the IR at the integrase end.

### Table 1: Antimicrobial Susceptibility of VIM-2 Producing Pseudomonas aeruginosa

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Date of isolation (mo-day-yr)</th>
<th>Specimen source</th>
<th>MIC (µg/ml)</th>
<th>Aztreonam</th>
<th>Meropenem</th>
<th>Colistin</th>
<th>Polymyxin B</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3-24-12 Foot wound</td>
<td></td>
<td>&gt;16</td>
<td>&gt;8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>5-4-12 Sputum</td>
<td></td>
<td>4</td>
<td>&gt;8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>5-16-12 Urine</td>
<td></td>
<td>&gt;16</td>
<td>&gt;8</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>9-1-12 Blood</td>
<td></td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>9-17-12 Sputum</td>
<td></td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>3-12-13 Urine</td>
<td></td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>5-7-13 Sputum</td>
<td></td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

*Isolates were also resistant to piperacillin-tazobactam (MIC > 64/µg/ml), cefepime (MIC > 16 µg/ml), ceftazidime (MIC > 16 µg/ml), imipenem (MIC > 8 µg/ml), levofloxacin (MIC > 8 µg/ml), ciprofloxacin (MIC > 2 µg/ml), gentamicin (MIC > 8 µg/ml), tobramycin (MIC > 8 µg/ml), and amikacin (MIC > 32 µg/ml). The sputum isolate from case 2 and isolates from cases 4, 5, 6, and 7 were interpreted as susceptible. The wound isolate from case 1, both isolates from case 2, and isolates from cases 4, 5, 6, and 7 were interpreted as susceptible. All isolates were interpreted as susceptible.*
(IRi) and the IR at the transposon end (IRt). BLAST results show only four nucleotide differences (>99.9% identity) with the partial sequence of integron In559 (GenBank accession number KC821786) and a novel IS element, designated ISPa54, present in the In11 gene. The mer operon (4.5 kb), located downstream of the blacIM-harboring integron, is nearly identical (>99.9% identity) to that from a P. aeruginosa strain C79 genomic island (GenBank accession number JF826498), suggesting a hybrid transposon structure.

The downstream region is a 16-kb integron-like element, with its overall structure resembling that of the integron-like element identified in Salmonella genomic island 2 (SGI2) in Salmonella enterica subsp. enterica serovar Emek (32). The only difference between the two integrons is that in the isolate from this study, a blaOXA-4a-adA2-cmlA6 gene array replaces the dfrA1-orfC gene array found in SGI2. The rest of this region, located within the 5' conserved segment and the fragment from qacED1 to IS6100 [12.5 kb]) shows >99.9% identity to that of SGI2. There is also an extra IRt close to IS6100 in an In4-like structure.

A 913-bp fragment, located between the above-described Tn501-like transposon and the 16-kb integron-like element, is identical to part of P. aeruginosa strain C plasmid pKLC102 transposon TNC23 (GenBank accession number AY257539), carrying a putative resolvase gene, res. Interestingly, the res gene of the strain in this study was disrupted by the mer operon at 826 bp downstream of the start codon. A third 38-bp Tn3-like transposon IR was found immediately abutting this truncated res gene. PCR assays confirmed the presence of the same genomic island in all isolates.

**DISCUSSION**

Through laboratory-based surveillance, we uncovered the presence of genetically related XDR P. aeruginosa harboring VIM-2 in seven patients from a regional hospital system in northeast Ohio. Alarming, the XDR phenotype expressed by some of these isolates precluded any reliable antibiotic treatment since they even displayed intermediate resistance to colistin, an “agent of last resort.” Aztreonam, a monobactam usually stable against MBLs, was not consistently active either. Patients who were affected had multiple comorbidities, endured prolonged colonization, required long-term care, and, in one instance, had a lethal outcome from a bloodstream infection. The epidemiological link among these genetically related isolates appears to be admission to a community hospital and residence in long-term-care facilities in northeast Ohio, with the exception of a patient who was transferred to the tertiary medical center from Qatar. After the detection of MBL-producing P. aeruginosa by the clinical microbiology laboratory, enhanced infection control precautions and contact isolation were implemented. Despite ongoing surveillance 12 months after the last case, no additional cases have been detected.

All P. aeruginosa isolates in this report belonged to ST233 and contained blacIM-2 in the In559 cassette array. The gene array in this class 1 integron is almost identical to genes characterized in P. aeruginosa isolates from an outbreak in 2003 at John H. Stroger, Jr., Hospital of Cook County in Chicago, IL (isolate 7052; GenBank accession number Y943084) (12). The same genetic element was detected in Norway (GenBank accession number FM165436) in P. aeruginosa ST233 imported from Ghana (33), in a P. aeruginosa isolate from Taiwan (isolate S1-36) (34), and in P. aeruginosa ST235 from Russia (GenBank accession number DQ522233). We note that P. aeruginosa ST233 and ST235 do not share any alleles (http://pubmlst.org/paeruginosa). Recently, the widespread dissemination of P. aeruginosa ST235 harboring blacIM-2 in a similar array was described in Russia and its neighboring region, as well as in several Asian countries (35, 36). Other high-risk clones of VIM-producing P. aeruginosa have also spread successfully (37); for instance, P. aeruginosa ST175 harboring VIM-2 has been detected in Spain, France, and Central Europe (23, 38–41).
Further in-depth analyses of our strains revealed that the bla-VIM-2 gene was located in a complex 35-kb genomic island, consisting of integron In559 embedded in a Tn501-like transposon, and located in the chromosome of *P. aeruginosa*. Adjacent to this structure we found genetic elements homologous to SGII, a large genetic element first seen in *Salmonella*. Horizontal gene transfers between *Salmonella* and other nonfermenters have been previously documented in clinical isolates, but none of these transfers resulted in a genetic element with the size and complexity of the one we found (42). Mobile genetic elements similar to those of *Salmonella* found in our *P. aeruginosa* strain have also been identified in the chromosome of *Acinetobacter baumannii* (43). Our finding raises concerns about recombination events between bacterial species of diverse clinical, animal, and environmental origins that may result in the propagation of antibiotic resistance determinants (44). *Salmonella enterica* carrying the VIM-2 MBL has been detected in Morocco, where the multidrug-resistant (MDR) *S. enterica* serovar Kentucky is prevalent (45).

The detection of an international clone of VIM-2-producing *P. aeruginosa* in different components of a health care system in our region heralds the potential threat of widespread dissemination of MBLs in northeast Ohio and beyond. The presence of a single clone and the epidemiological association with patients affected by multiple comorbidities and heavily exposed to health care are reminiscent of outbreaks of two other frequently carbapenem-resistant species, *A. baumannii* and *Klebsiella pneumoniae*, which emerged in the United States during the past decade (46, 47). The dissemination of these highly resistant pathogens underscores the vulnerability of our patients and health care system, making more urgent the lack of effective antibiotic therapies and the current crisis in antibiotic development (19, 48).

At present, disciplined adherence to infection control practices and prudent use of antibiotics remain the best strategies to prevent the emergence of VIM-producing *P. aeruginosa*. Although efforts and resources in this regard are increasingly deployed in the acute-care setting, significant challenges are faced in community and long-term-care facilities (49). This report highlights the important role of laboratory surveillance enhanced with detailed genetic characterization in identifying emerging resistant phenotypes at the local and regional levels (50). These efforts led to the identification of a novel recombination event resulting from a Tn501-like transposon and SGII, expanding our understanding of the molecular epidemiology of MBL-producing *P. aeruginosa*.

ACKNOWLEDGMENTS

Funds and facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program (award I101BX001974), and the Geriatric Research Education and Clinical Center VISN 10 supported this work. R.A.B. and B.N.K. received funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI072219, R01AI063517, R01AI100560, R01AI090155, and UM1AI104681. F.P. is supported by a European Research Council starter grant (RESISTOME 260276).

Funding organizations were not involved in the design and conduct of the study, the collection, analysis, and interpretation of the data, or the preparation, review, or approval of the manuscript. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or the Department of Veterans Affairs.

REFERENCES


October 2014 Volume 58 Number 10


